

**Single-Cell Mutation
Monitoring Systems**
Methodologies and Applications

Edited by

AFTAB A. ANSARI

Northrop Services, Inc.

Research Triangle Park, North Carolina

and

FREDERICK J. DE SERRES

Single-Cell Mutation Monitoring Systems

Methodologies and Applications

Edited by

AFTAB A. ANSARI

*Northrop Services, Inc.
Research Triangle Park, North Carolina*

and

FREDERICK J. DE SERRES

*National Institute of Environmental Health Sciences
Research Triangle Park, North Carolina*

PLENUM PRESS • NEW YORK AND LONDON

Library of Congress Cataloging in Publication Data

Main entry under title:

Single-cell mutation monitoring systems.

(Topics in chemical mutagenesis; v. 2)

Includes bibliographical references and index.

I. Mutagenicity testing. I. Ansari, Aftab A. II. de Serres, Frederick J. III. Title: Mutation monitoring systems: methodologies and applications. IV. Series.

QH465.C5S56 1984

574.87/322

84-3368

ISBN 0-306-41537-2

©1984 Plenum Press, New York
A Division of Plenum Publishing Corporation
233 Spring Street, New York, N.Y. 10013

All rights reserved

No part of this book may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, microfilming, recording, or otherwise, without written permission from the Publisher

Printed in the United States of America

Contributors

- RICHARD J. ALBERTINI, Department of Medicine, University of Vermont College of Medicine, Burlington, Vermont 05405
- JAMES W. ALLEN, Genetic Toxicology Division, Health Effects Research Laboratory, U. S. Environmental Protection Agency, Research Triangle Park, North Carolina 27711
- AFTAB A. ANSARI, Northrop Services, Inc., Research Triangle Park, North Carolina 27709
- MASROOR A. BAIG, Laboratory of Genetics, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709; *present address:* Department of Biochemistry, University of Kashmir, Hazratbal, Srinagar 190006, India
- WILLIAM L. BIGBEE, Lawrence Livermore National Laboratory, Biomedical Sciences Division, University of California, Livermore, California 94550
- ELBERT W. BRANSCOMB, Lawrence Livermore National Laboratory, Biomedical Sciences Division, University of California, Livermore, California 94550
- MARTHA BRICE, Division of Medical Genetics, University of Medicine, University of Washington, Seattle, Washington 98195
- KAREN BROCK, Northrop Services, Inc., Research Triangle Park, North Carolina 27709
- JAMES CAMPBELL, Northrop Services, Inc., Research Triangle Park, North Carolina 27709
- MARGARET FARQUHAR, Division of Medical Genetics, Department of Medicine, University of Washington, Seattle, Washington 98195
- HOWARD G. GRATZNER, Institute for Cell Analysis, Department of Medicine, University of Miami School of Medicine, Miami, Florida 33124
- ROBERT W. KAPP, Jr., East Laboratory, Bio/dynamics, Inc., East Millstone, New Jersey 08873

- PHILIP C. KELLEHER, Department of Medicine, University of Vermont College of Medicine, Burlington, Vermont 05405
- MARVIN S. LEGATOR, Division of Environmental Toxicology, Department of Preventive Medicine and Community Health, The University of Texas Medical Branch, Galveston, Texas 77550
- DALE LINDSLEY, Division of Medical Genetics, Department of Medicine, University of Washington, Seattle, Washington 98195
- BERNHARD E. MATTER, Sandoz Ltd., Preclinical Research, Toxicology, CH-4002 Basle, Switzerland
- JON C. MIRSALIS, Cellular and Genetic Toxicology Department, SRI International, Menlo Park, California 94025
- ANN D. MITCHELL, Cellular and Genetic Toxicology Department, SRI International, Menlo Park, California 94025
- BETTY NAKAMOTO, Division of Medical Genetics, Department of Medicine, University of Washington, Seattle, Washington 98195
- PETER NUTE, Department of Anthropology, University of Washington, Seattle, Washington 98195
- THALIA PAPAYANNOPOULOU, Division of Hematology, Department of Medicine, University of Washington, Seattle, Washington 98195
- R. JULIAN PRESTON, Biology Division, Oak Ridge National Laboratory, Oak Ridge, Tennessee 37830
- ROBERT R. RACINE, Sandoz Ltd., Preclinical Research, Toxicology, CH-4002 Basle, Switzerland
- MATTHEW D. SCHARFF, Department of Cell Biology, Albert Einstein College of Medicine, Bronx, New York 10461
- YOUSUF SHARIEF, Northrop Services, Inc., Research Triangle Park, North Carolina 27709
- GEORGE STAMATOYANNOPOULOS, Division of Medical Genetics, Department of Medicine, University of Washington, Seattle, Washington 98195
- D. L. SYLWESTER, Biometry Facility, University of Vermont College of Medicine, Burlington, Vermont 05405
- DONALD J. ZACK, Department of Cell Biology, Albert Einstein College of Medicine, Bronx, New York 10461

Preface

There is general agreement that increased environmental pollution poses a potential health hazard to humans and that effective control of such genetic injury requires monitoring the exposed individuals for genetic damage and identifying chemicals that may cause mutation or cancer. Tests available for identifying mutagens or carcinogens range from relatively simple, rapid assays in prokaryotes and test systems utilizing mammalian cells in tissue culture to highly elaborate tests in intact animals. No single test can provide data for an unequivocal assessment of the mutagenicity of a given chemical and the risk it might pose to human health. A tier approach, therefore, was suggested for mutagenicity testing in which the suspected agents would be initially evaluated with simple, inexpensive tests that would give qualitative results. Chemicals found to be positive in the first-tier testing would then be evaluated with more complex tests, including those based on mammalian cells in culture. Testing in the final tier requires whole-animal studies, and is expensive and time-consuming, and even the results from these studies need to be extrapolated for human risk assessment.

The mutation systems based on whole animals require scoring large numbers of animals, and therefore are not practical for the routine testing of mutagens. As an alternative to monitoring the pedigree, cells from exposed individuals may be considered for screening for point mutations through the use of an appropriate marker protein. The advantage of such a single-cell screening system (cell specific-locus test) would be that each cell, rather than each individual, could be examined for mutational events.

Single-cell mutation monitoring systems are the ones that detect mutational events in individual cells rather than whole animals. A few single-cell mammalian mutation systems have been developed and are in use in various laboratories. Several others are in various stages of development. The purpose of this book is to bring together such mutation detection methods. Special attention has been paid to include enough experimental details to allow easy

adaptation of the techniques by different investigators. Each chapter is divided into sections comprised of experimental details and sample results.

Each chapter in this book describes a mutation monitoring system that uses one of the easily available cell samples from animals or humans, e.g., red blood cells, lymphocytes, and spermatozoa. The Chapters 1-3 and 9 describe methods based on the use of red blood cells. Six chapters describe methods that use lymphocytes. The last chapter is based on the use of spermatozoa.

Aftab A. Ansari

Frederick J. de Serres

Research Triangle Park, North Carolina

Contents

Chapter 1. Somatic-Cell Mutation Monitoring System Based on Human Hemoglobin Mutants	1
GEORGE STAMATOYANNOPOULOS, PETER NUTE, DALE LINDSLEY, MARGARET FARQUHAR, MARTHA BRICE, BETTY NAKAMOTO, AND THALIA PAPAYANNOPOULOU	
1. Introduction	1
1.1. The Approach	1
1.2. Previous Studies	2
1.3. Requirements of a Red Cell Screening System	3
2. The Hemoglobin Mutants	3
2.1. Hemoglobin Loci	3
2.2. Types of Mutations	4
3. Hemoglobin in Mutation Research: Gametal Mutation Rates	6
3.1. Indirect Estimates	6
3.2. Direct Estimates	7
4. A System for Detecting Somatic Mutations of Hemoglobin	8
4.1. Appropriate Mutants	8
4.2. Immunochemical Detection of Abnormal Hemoglobins in Single Cells	9
4.3. Detection of Rare Mutant Red Cells by Fluorescent Microscopy	12
4.4. Screening for "S Cells" or "C Cells" in Blood of Genetically A/A Subjects	15
4.5. Minimum Frequencies of Somatic Mutations at Globin-Chain Loci	17
4.6. Relationship between Somatic Mutation Frequencies and Gametal Mutation Rates	18

4.7. Relationship between Frequencies of Somatic-Cell Mutants and Compartments at Which Mutations Occur	19
5. Methodological Aspects: Monospecific Anti-Mutant-Hemoglobin Antibodies	20
5.1. Immunizations	20
5.2. Sepharose-Hb	21
5.3. Purification	21
5.4. Red Cell Labeling	23
6. Methodological Aspects: Monoclonal Anti-Globin-Chain Antibodies	24
6.1. Immunizations	24
6.2. Screening	24
6.3. Semiquantitative Assessment of Ab-Hb Binding	25
6.4. Mapping the Sites of Ab-Hb Binding	27
6.5. Possible Recognition of Mutant Hemoglobins in Animals	29
References	29

Chapter 2. Use of Fluorescence-Activated Cell Sorter for Screening Mutant Cells

37

WILLIAM L. BIGBEE AND ELBERT W. BRANSCOMB

1. Introduction	37
2. Immunologic Identification and Flow Detection of Erythrocytes Containing Amino Acid-Substituted Hemoglobin	38
2.1. Production of Antibodies	39
2.2. Suspension Labeling of Red Cells with Hemoglobin Antibodies	41
2.3. Flow Cytometric Processing	41
2.4. Results Using Hemoglobin S- and C-Specific Antibodies	45
3. Future of the Hemoglobin-Based Assay	50
4. Detection of Erythrocytes with Mutationally Altered Glycophorin A	51
4.1. Background	51
4.2. Gene Expression Loss Variants	51
4.3. Single-Amino Acid-Substitution Variants	54
5. Summary and Conclusions	55
References	56

Chapter 3. Development of a Plaque Assay for the Detection of Red Blood Cells Carrying Abnormal or Mutant Hemoglobins 59

MASROOR A. BAIG AND AFTAB A. ANSARI

1. Introduction	59
2. Principle of the Method	59
3. Reagents	62
3.1. Anti-Mouse RBC Ghost Sera	62
3.2. Anti-Mouse Hb Antibodies	63
3.3. Indicator Cells. Methods for Coupling Antibodies to Sheep RBC	71
3.4. Complement	72
4. Equipment	73
4.1. Plaque Chambers	73
4.2. Additional Materials	73
5. Procedure for the RBC-Antibody Plaque Assay	75
5.1. Factors Affecting the RBC Plaque Formation	75
5.2. Specificity of the RBC Plaque Assay	75
6. RBC-Protein A Plaque Assay	77
7. Conclusions	77
References	77

Chapter 4. Direct Assay by Autoradiography for 6-Thioguanine-Resistant Lymphocytes in Human Peripheral Blood 81

RICHARD J. ALBERTINI, PHILIP C. KELLEHER, AND
DAVID L. SYLWESTER

1. Introduction	81
1.1. Human Mutagenicity Monitoring	81
1.2. 6-Thioguanine-Resistant (TG ^r) Human Peripheral Blood T Lymphocytes (T-PBLs)	82
1.3. Direct Enumeration of TG ^r T-PBLs by Autoradiography	82
1.4. Phenocopies	83
2. Autoradiographic TG ^r T-PBL Assay Method	84
2.1. Cell Preparation	84
2.2. Cryopreservation	84
2.3. Cell Culture	85
2.4. Termination, Coverslip Preparation, and Autoradiography	85
2.5. Enumeration of TG ^r T-PBLs and Calculation of TG ^r T-PBL Variant Frequency (V_f)	87

3. Sample Results	87
3.1. TG ^r T-PBL V_f Assay: Appearance of Slides	87
3.2. TG ^r T-PBL V_f Assay: Sample Data	89
4. Statistical Analysis Methods	89
4.1. Notation and Basic Assumptions	89
4.2. Confidence Intervals for a Single Variant Frequency	91
4.3. Confidence Intervals for Ratios of Variant Frequencies	92
4.4. Sample Size Determinations	93
5. Discussion	94
References	95

Chapter 5. Application of Antibodies to 5-Bromodeoxyuridine for the Detection of Cells of Rare Genotype 99

HOWARD G. GRATZNER

1. Introduction	99
1.1. Flow Cytometry	100
1.2. The Use of 5-Bromodeoxyuridine for the Detection of Cell Proliferation	101
2. Materials and Methods	101
2.1. Cell Culture	101
2.2. Labeling with BrdUrd	102
2.3. Immunological Methods	102
2.4. Flow Cytometry	105
2.5. Hybridoma Production	105
3. Results	106
3.1. Determination of Antibody Specificity	106
3.2. Flow Cytometric Method for Immunofluorescent Detection of DNA Replication	109
3.3. Application of the Flow Immunofluorometric Anti-BrdUrd Technique to the Assessment of DNA Damage	113
3.4. Reconstruction Experiments for the Detection of Thioguanine-Resistant Variants by the Immunofluorescent Anti-BrdUrd Method	117
3.5. Preparation of Monoclonal Antibodies against 5-Bromodeoxyuridine or 5-Iododeoxyuridine	120
4. Discussion	121
5. Summary	123
References	124

Chapter 6. Cytogenetic Abnormalities as an Indicator of Mutagenic Exposure	127
R. JULIAN PRESTON	
1. Introduction	127
2. Lymphocyte Assay Methodology	128
2.1. <i>In Vitro</i> Cultures	128
2.2. Sampling Time	129
2.3. Fixation and Slide Preparation	131
2.4. Analysis of Cells	131
3. Chromosome Aberration Analysis Following Radiation or Chemical Exposure	133
3.1. The Sensitivity of the Lymphocyte Assay	133
3.2. Background Aberration Frequencies and "Matched" Control Groups	137
4. The Analysis of Bone Marrow Samples	138
5. The Plausibility of Estimating Genetic or Carcinogenic Risk from Aberration Frequencies in Lymphocytes	139
6. Concluding Remarks	141
References	141
Chapter 7. Sister Chromatid Exchange Analysis in Lymphocytes	145
JAMES W. ALLEN, KAREN BROCK, JAMES CAMPBELL, AND YOUSUF SHARIEF	
1. Introduction	145
2. Methodology	147
2.1. Background	147
2.2. General Design Considerations	150
2.3. Technical	153
3. Selected Applications	155
Appendix A. A Procedure for Growing and Preparing Human Lymphocytes for SCE Analysis	157
Appendix B. A Procedure for Growing and Preparing Rat Lymphocytes for SCE Analysis	158
References	159

Chapter 8. Unscheduled DNA Synthesis as an Indication of Genotoxic Exposure	165
ANN D. MITCHELL AND JON C. MIRSALIS	
1. Introduction	165
2. Four Laboratory Approaches to Measuring Unscheduled DNA Synthesis	168
2.1. Liquid Scintillation Counting Measurements of UDS in Human Fibroblast DNA	168
2.2. Autoradiographic Measurements of UDS in Human Diploid Fibroblasts	171
2.3. Autoradiographic Measurements of UDS in Primary Cultures of Rat Hepatocytes	175
2.4. Measurements of UDS in Hepatocytes following <i>in Vivo</i> Treatment	176
3. Methods	180
3.1. Procedures for LSC UDS Assays	180
3.2. Establishment of Primary Cultures of Rat Hepatocytes from Treated or Untreated Animals	187
3.3. The <i>in Vivo</i> Rat Hepatocyte UDS Assay	191
3.4. Autoradiography	192
4. Reagents, Solutions, Stains, and Media	196
4.1. Reagents	196
4.2. Solutions and Stains	200
4.3. Media	207
5. Equipment and Supplies	208
5.1. Balances	208
5.2. Calculators	209
5.3. Centrifuges	209
5.4. Computer Equipment	209
5.5. Filters	209
5.6. Grain Counters	209
5.7. Incubators and Related Apparatus	210
5.8. Laminar-Flow Hoods	210
5.9. Microscopes	210
5.10. Mixer	210
5.11. Pipetting Apparatus	210
5.12. Pump Apparatus	211
5.13. Rocker Platform	211
5.14. Scintillation Counter	211
5.15. Spectrophotometer	211

5.16. Tissue Culture Supplies	211
5.17. Water Baths	211
5.18. Water System	212
5.19. Miscellaneous Equipment	212
5.20. Miscellaneous Supplies	212
References	213

Chapter 9. The Micronucleus Test as an Indicator of Mutagenic Exposure

217

ROBERT R. RACINE AND BERNHARD E. MATTER

1. Historical Background	217
2. Rationale of the Test System	218
3. Technical Procedure	220
3.1. Animals	220
3.2. Administration of the Test Substance	220
3.3. Determination of Dosage	221
3.4. Sampling Times	221
3.5. Preparation of the Bone Marrow Smears	222
3.6. Scoring of Micronuclei	223
3.7. Data Evaluation	224
3.8. Other Useful Information on the Micronucleus Test	225
3.9. Manpower and Costs	225
4. Results and Comparative Studies	225
5. Related Assay Systems	226
6. Advantages	227
7. Limitations	227
8. Application of the Micronucleus Test	228
References	228

Chapter 10. The Identification of Somatic Mutations in Immunoglobulin Expression and Structure

233

DONALD J. ZACK AND MATTHEW D. SCHARFF

1. Introduction	233
2. Immunoglobulin Protein and Gene Structure	234
3. Methods for the Isolation of Mutants	237

3.1. Mutagenesis	237
3.2. Screening Techniques	239
3.3. Selective Techniques	249
4. Frequency and Phenotypes of Mutants	251
4.1. Frameshift Mutants	252
4.2. Point Mutants	253
4.3. Internal Deletion Mutants Associated with Changes in DNA or RNA	255
4.4. Class- and Subclass-Switch Mutants	255
5. Discussion	257
References	259

Chapter 11. Detection of Chemically Induced Y-Chromosomal Nondisjunction in Human Spermatozoa 265

MARVIN S. LEGATOR AND ROBERT W. KAPP, JR.

1. Introduction	265
2. Background	266
3. Agents That Increase YFF Bodies in Human Sperm	268
3.1. Methodology	268
3.2. Results to Date	269
4. Discussion	273
References	276

Index	279
-------	-----

Somatic-Cell Mutation Monitoring System Based on Human Hemoglobin Mutants

GEORGE STAMATOYANNOPOULOS, PETER NUTE,
DALE LINDSLEY, MARGARET FARQUHAR, MARTHA BRICE,
BETTY NAKAMOTO, AND THALIA PAPAYANNOPOULOU

1. INTRODUCTION

1.1. The Approach

The system described in this chapter was developed as a means of detecting rare red cells, in genetically normal (HbA/HbA) individuals, that are heterozygous for an abnormal hemoglobin. It is assumed, first, that mutations arise spontaneously in human hemopoietic stem cells, as they do in gametal stem cells, and second, that somatic mutations of globin-chain genes do not diminish the viability of affected stem cells. The latter assumption is a reasonable one, since phenotypic expression of such mutations occurs very late in hemopoietic cell differentiation. It is expected that as a result of these stem cell mutations, lines of stem cells containing the mutant globin genes are established and produce erythrocytes heterozygous for structurally abnormal globin chains. Development of appropriate methods of screening blood samples should then permit

GEORGE STAMATOYANNOPOULOS, DALE LINDSLEY, MARGARET FARQUHAR, MARTHA BRICE, AND BETTY NAKAMOTO • Division of Medical Genetics, Department of Medicine, University of Washington, Seattle, Washington 98195. THALIA PAPAYANNOPOULOU • Division of Hematology, Department of Medicine, University of Washington, Seattle, Washington 98195. PETER NUTE • Department of Anthropology, University of Washington, Seattle, Washington 98195.

detection and enumeration of red cells that contain an abnormal hemoglobin as a result of somatic mutation in a stem cell.

In principle, an efficient and sensitive method for detecting mutant erythrocytes in genetically normal persons would be of significant value to mutation research, since the study of but a few subjects would be required to assess mutagenic effects of various environmental agents. Similarly, the monitoring of populations for the effects of known mutagens would require longitudinal studies of only a few persons. Since the effects of mutagens on human subjects could be studied directly, the relevance of such studies to human health problems would be apparent. Questions concerning age- or sex-related differences in metabolism or the possibility of polymorphic variation in systems involved in biotransformation of mutagens could be investigated in studies of both populations and families. Finally, a system for scoring somatic mutants of hemoglobin in animal models could be used to correlate frequencies of somatic and gametal mutation.

1.2. Previous Studies

Detection of red cells bearing somatic mutations was first attempted by Atwood⁽¹⁾ and Atwood and Scheinberg.^(2,3) They noted that a small proportion (about one in 10^3) of erythrocytes from subjects of blood type AB or A failed to carry the agglutinin A. Such cells were originally regarded as somatic mutants. On these grounds, Atwood and Scheinberg⁽²⁾ calculated a somatic mutation rate of 7×10^{-6} per cell division. The mutational origin of the abnormal red cells was subsequently tested by measuring the frequencies of non-A or non-B erythrocytes in AB heterozygotes and BB homozygotes.⁽⁴⁾ If the abnormal cells were mutants, their frequency in BB homozygotes should have equaled the square of their frequency in AB heterozygotes. Although BB homozygotes had fewer abnormal cells than did the heterozygous subjects, the frequency of these cells was 50–200 times higher than expected. These findings suggested that it is unlikely that the absence of an A or B agglutinin from a rare red cell represents the outcome of a somatic-cell mutation.

Sutton^(5,6) attempted to relate the presence of red cells with the phenotype characteristic of hereditary persistence of fetal hemoglobin (HPFH; Section 2.2) to the occurrence of somatic mutations. This condition is associated with continuation of synthesis of fetal hemoglobin in all circulating red cells of adult carriers of the abnormal gene. Rare red cells (F cells) that contain fetal hemoglobin are also found in persons who are not carriers of an HPFH determinant. It was postulated that F cells were somatic mutants.^(5,6) Results of studies, using sensitive methods, render this a highly unlikely possibility, since F cells constitute from 0.5% to 5.0% of the erythrocytes in every normal adult,^(7,8) and their frequencies are elevated in various states, including anemias and hemo-